|Description||CO-1686 hydrobromide is the hydrobromide salt form of CO-1686. CO-1686, also called as Rociletinib, is an oral tyrosine kinase inhibitor that irreversibly and selectively inhibits mutation of EGFR for treating Non-small cell lung cancer.Non-small cell lun|
|Appearance||Light yellow to yellow Solid|
|Synonyms||N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide;hydrobromide CO-1686 (hydrobromide) CO-1686 hydrobromide HY-15729A CS-5247 KB-310894 1446700-26-0|
|Solubility||Soluble to ≥ 59 mg/mL in DMSO|
|Storage||Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -60℃ for long term (months to years).|
|Shelf Life||2 years|
|Current Developer||Clovis Oncology; Genentech|
Butein, a plant polyphenol isolated from Rhus verniciflua, is able to inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, also inhibits EGFR. Th...
AV-412 is a dual EGFR/ErbB2 kinase inhibitor. It completely inhibits the tumor growth of both H1650 and H1975 xenografts in nude mice. It is proved that AV-412 ...
Afatinib Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, res...
AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth facto...
BMS-690514 is a potent inhibitor of human epidermal growth factor receptor (HER) 1 (EGFR), 2, and 4, and vascular endothelial growth factor receptors (VEGFR) 1-...
XL647 is an orally bioavailable small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. It inhibits EGFR, HER2, VEGFR and EphB...
Varlitinib, also known as ARRY-543, is an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. V...
AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of
AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...
MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the...
RG13022, a non-phenolic tyrphostin analog, is an epidermal growth factor (EGF) receptor tyrosine kinase inhibitor with potential antiproliferative effect.
Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinic...
Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA M...
SKLB1028 is a novel Bcr-abl tyrosine kinase inhibitor, Epidermal growth factor inhibitor and Fms-like tyrosine kinase 3 inhibitor originated by CSPC Ouyi Pharma...
PD153035 is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src.
This active molecular is an irreversible EGFR ( epidermal growth factor receptor ) tyrosine kinase inhibitor. Transtinib shows good anti-proliferative activity ...
PF-06747775, a methylpurin derivative, has been found to be an epidermal growth factor receptor antagonist and could probably be effective against cell lung can...
Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
BGB-283 is a selective Epidermal growth factor receptor and Proto oncogene protein b raf inhibitor under the development of BeiGene. BGB-283 shows antitumor act...